Zimmer Biomet Holdings, Inc. (ZBH)

The company now

Zimmer Biomet reported third-quarter net sales of $2.063 billion on 4 November 2026, up 3.1 percent from the prior year and up 3.7 percent at constant currency (exchange-rate effects removed) 1.

Diluted earnings per share were $1.00, down 13.8 percent, while adjusted earnings per share of $1.90 matched the prior year 1. Operating profit was $307.6 million against $351.3 million a year earlier 1.

Chief executive Ivan Tornos said the Hips, sports and extremities, and technology and bone cement lines, two-thirds of the business, grew at upper single digit or double-digit rates 1. Knees sales fell 3.1 percent to $767.5 million 1.

The company updated its full-year guidance and now expects organic constant currency revenue growth of 3.0 percent to 3.5 percent, against 2.25 percent to 3.25 percent before 1. It expects adjusted earnings per share of $8.50 to $8.60 1.

On 8 September the company said Kevin Thornal, Group President, Global Businesses and the Americas, would leave on 30 September 2. It promoted Gary Campbell, Brian Hatcher and Bradley Kessler to run the Americas and the global business groups 2.

As of Nov 4, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.